The U.S. envoy for North Korea arrived in South Korea on Saturday amid stalled denuclearisation talks and tension over Pyongyangs recent missile tests.Special Representative Sung Kims visit came days after North Korea fired a new submarine-launched ballistic missile SLBM , which prompted criticism from Washington and calls for a return to talks aimed at denuclearising the North in return for U.S. sanctions relief.Kim, after talks in Washington with South Korean and Japanese counterparts on Tuesday, urged North Korea to refrain fr <a href=https://www.cup-stanley.uk>stanley mugs</a> om further provocations and engage in sustained and substantive dialogue. Pyongyang so far has rejected U.S. overtures, accusing the United States and South <a href=https://www.stanley-mug.us>stanley cup</a> Korea of talking diplomacy while ratcheting up tensions with their own military activities.On Thursday, the North said the United States was overreacting to its self-defensive SLBM test and questioned the sincerity of Washingtons offers of talks, warning of consequences.Arriving in South Korea, Kim said he looks forward to having productive follow up discussions with his counterpart, without elaborating. Follow Cyprus Mailon Google News missilesNorth KoreaSouth Korea Share: Reuters News Service In case you missed it Monday 30 June | 16:23 Cyprus cyclist battles injury to complete Mountain of Hell race By Sena Chang Sunday 29 June | 13:49 Oh, the romance of living in the Cyprus countryside By Re <a href=https://www.stanley-cups.fr>stanley thermos</a> bekah Gregoriades Okpj Cyprus Business Now
TRENTON, N.J. 鈥?Pfizer Inc.s just-approved Xalkori, the first new medicine in more than six years for deadly lung cancer, proves the value of precisely targeting rare diseases linked to gene variants, cancer specialists and Pfizer executives said Tuesday.The drug, approved last Friday in the U.S. along with a companion diagnostic test for just a small subset of lung cancer patients, epitomizes drugmakers new strategy of developing very expensive but effective medicines for the few to replace the blockbusters for the masses now getting generic competition.Its also part of the long-awaited advent of personalized medicine, in which doctors identify patients with gene changes or variations that fuel their disease and then try to match them with new medicines that specifically target those genes. This is a paradigm shift, Dr. Paul A. Bunn Jr., a University of Colorado professor and cancer r <a href=https://www.stanleycups.ro>stanley cup</a> esearcher involved in testing Xalkori, told journalists during a conference call hosted by Pfizer. It used to be that everybody with cancer was treated the same with surgery and chemotherapy.Xalkori, a pill with relativ <a href=https://www.stanleycups.ro>stanley cupe</a> ely minor side effects compared to traditional infused chemotherapy, was approved for the roughly 4 percent of patients with non-small cell lung cancer who have whats called the ALK fusion gene.This change occurs whe <a href=https://www.cup-stanley.es>stanley spain</a> n ALK, short for anaplastic lymphoma kinase, and another gene on the same chromosome rearrange their positions and fuse together. That turns the ALK gene on constan